Immunotherapy

Papers
(The H4-Index of Immunotherapy is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Simulating a virtual tumor board with large language models: a pilot study in NSCLC patients receiving immunotherapy110
Imaging of brain metastases treated with immune checkpoint inhibitors38
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study29
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma28
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma23
Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study22
Identifying risk factors and biomarkers for severe CIP in lung cancer patients– a retrospective case series study22
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia22
Postvaccination immune-mediated hepatitis: what do we really know?21
Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data20
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-15820
Diagnostic and therapeutic evaluation of Blomia tropicalis in patients with allergic rhinitis19
Pd-1, Pd-L1, Ido, Cd70 and Microsatellite Instability as Potential Targets to Prevent Immune Evasion in Sarcomas19
Nivolumab induced discolouration of the tongue: a case report18
Therapeutic lymph node dissection with neoadjuvant immunotherapy for macroscopic melanoma – too much skin in the game?18
MicroRNA prognostic markers for immune checkpoint inhibitor success in urologic cancers18
The role of bronchoscopic cryoimmunotherapy in non-small cell lung cancer: current evidence and future perspectives18
4-1BB Antibody Enhances Cytotoxic Activity of Natural Killer Cells Against Prostate Cancer Cells Via NKG2D Agonist Combined with IL-2717
0.096449851989746